Retension Pharmaceuticals, Inc. - 8-K Filing
Retension Pharmaceuticals reports Q3 2026 net loss of $5.9M and announces $51.75M gross proceeds from upsized October IPO (Items: 2.02 of this Current Report on Form 8-K, including Exhibit 99, 9.01 Financial Statements and Exhibits)
Tickers: $RTSN
Read the full article at SEC EDGAR
Part of the story Retension Pharmaceuticals Reports Q3 GAAP EPS of -$7.33 and Announces IPO Proceeds (2 articles)